2024-10-10 23:32:00
The French laboratory has chosen to open exclusive negotiations with the American CD&R, which has offered more than 15 billion euros for the acquisition “50% or more” of its subsidiary Opella, which produces in particular Doliprane.
The French Minister of Industry, Marc Ferracci, “took note” In the evening of Thursday 10 October, the decision of the pharmaceutical group Sanofi, reported by the media, to start exclusive negotiations with the American fund CD&R in the context of the sale of Opella, which produces Doliprane. “After the announcement in the press of Sanofi’s choice to enter into exclusive negotiations with CD&R in the context of the sale of Opella”the minister “takes note of this decision, reminding both parties of the government’s vigilance points, both on an economic and health level”according to a reaction sent to AFP by his ministry.
The economic newspaper The Echoes reported that Sanofi’s board of directors has decided “initially open exclusive negotiations with the American fund”which offered more than 15 billion euros for the acquisition “50% or more” of the subsidiary dedicated to consumer health of the French group. Contacted by AFP, Sanofi did not confirm but specified that the communication is expected on Friday. This business, which includes more than a hundred brands, including Doliprane, Dulcolax, Lysopaïne and even Maalox, is present in 150 countries. It achieved a turnover of 5.2 billion euros in 2023.
This sales proposal does not call into question either the production in France of Doliprane or other essential medicines produced by Opella in our territory, nor the supply of these medicines to the market. »
Marc Ferracci, French Minister in charge of Industry
Marc Ferracci describes CD&R as “serious investment fund that presents positive prospects for the overall development of Opella and for the factories established in France”. Also remember “that a certain number of economic commitments will be required from Sanofi and the future buyer CD&R” aimed at guaranteeing the “maintain offices and decision-making centers on the national territory” et “Opella’s French industrial footprint”. In his statement the minister reiterates this “The State mobilizes all the tools at its disposal”, including the procedure for the control of foreign investments in France. “This sales proposal does not call into question either the production in France of Doliprane or other essential medicines produced by Opella in our territory, nor the supply of these medicines to the market”ensures. “This is naturally part of the required commitments.”
Sanofi has been thinking since autumn 2023 about how to separate from this entity. Faced with the American fund, another offer was made by the French fund PAI Partners. The pharmaceutical group will publish its quarterly financial results next week. The CD&R project provides, according to The Echoesthat Sanofi has retained a very significant share of the capital since then“could remain invested at about half of its division”.
#Sanofi #plans #sell #Doliprane #American #fund #government #takes #note